株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙SALE
市場調査レポート

世界のタンパク質治療薬市場:2017〜2021年

Global Protein Therapeutics Market 2017-2021

発行 TechNavio (Infiniti Research Ltd.) 商品コード 345849
出版日 ページ情報 英文 128 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.77円で換算しております。
Back to Top
世界のタンパク質治療薬市場:2017〜2021年 Global Protein Therapeutics Market 2017-2021
出版日: 2016年12月30日 ページ情報: 英文 128 Pages
概要

治療用タンパク質は、タンパク質欠乏症などの様々な疾患、癌、関節リウマチなどの慢性疾患の治療に広く用いられます。世界のタンパク質治療薬市場は、2017〜2021年にかけCAGR7.86%で拡大すると予測されています。

当レポートでは、世界のタンパク質治療薬市場について調査し、市場の動向と課題、製品別、治療分野別、タンパク質機能別、および地域別動向、2021年までの市場成長見通し、主要ベンダーのプロファイルなどをまとめています。

第1章 エグゼクティブサマリー

第2章 当レポートの範囲

第3章 市場調査方法

第4章 イントロダクション

第5章 市況

  • 市場概要
  • ファイブフォース分析

第6章 製品別市場セグメンテーション

  • モノクローナル抗体
  • ヒトインスリン
  • 凝固因子
  • EPO
  • ヒト成長ホルモン

第7章 治療分野別市場セグメンテーション

  • 代謝性疾患および内分泌疾患
  • 造血
  • 不妊症
  • 自己免疫疾患
  • 感染症
  • タンパク質ワクチン

第8章 タンパク質機能別市場セグメンテーション

  • 酵素活性および制御活性
  • 特殊標的活性
  • ワクチン
  • タンパク質診断

第9章 地域別セグメンテーション

  • 南北アメリカ
  • 欧州・中東・アフリカ
  • アジア太平洋地域

第10章 市場促進因子

第11章 促進因子の影響

第12章 市場の課題

第13章 促進因子と課題の影響

第14章 市場動向

第15章 ベンダー環境

  • 競合シナリオ
  • 市場シェア分析:2016年
  • その他の注目すべきベンダー

第16章 主要ベンダー分析

  • F. Hoffmann-La Roche
  • Novo Nordisk
  • Amgen
  • AbbVie
  • Johnson & Johnson
  • Merck

第17章 付録

第18章 Technavioについて

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: IRTNTR11316

About Protein Therapeutics

Therapeutic proteins are used to effectively treat a wide array of diseases such as protein deficiency diseases; chronic diseases such as cancer, rheumatoid arthritis (RA), ankylosing spondylitis, diabetes; infections such as human immunodeficiency virus (HIV), hepatitis A, hepatitis B, and hepatitis C; and other medical conditions such as genetic disorders, anemia cases related to kidney dialysis, and cancer-related anemia. Therapeutic proteins mostly consist of recombinant forms of naturally occurring proteins.

Technavio's analysts forecast the global protein therapeutics market to grow at a CAGR of 7.86% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global protein therapeutics market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of branded and biosimilar drugs used for the treatment of various diseases. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of the marketed drugs during the forecast period.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Protein Therapeutics Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • AbbVie
  • Amgen
  • F. Hoffmann-La Roche
  • Johnson & Johnson
  • Merck
  • Novo Nordisk

Other Prominent Vendors

  • Anhui Anke Biotechnology (Group)
  • AstraZeneca
  • Baxter International
  • Biocon
  • Biodel
  • BioGenomics
  • Biopartners
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Celltrion
  • Chugai Pharmaceutical
  • Diamyd Medical
  • Diasome Pharmaceuticals
  • DiaVacs
  • Dynavax Technologies
  • Eli Lilly
  • Ferring Pharmaceuticals
  • Generex Biotechnology
  • GeneScience Pharmaceuticals
  • Hualan Biological Engineering
  • Intas Pharmaceuticals
  • Ipsen
  • JCR Pharmaceuticals
  • Kyowa Hakko Kirin
  • Lexicon Pharmaceuticals
  • LG Life Sciences
  • MacroGenics
  • MannKind
  • Oramed Pharmaceuticals
  • Osiris Therapeutics
  • Pfizer
  • Sandoz International
  • Sanofi
  • Teva Pharmaceutical Industries
  • Thermalin Diabetes
  • Tolerion
  • Wockhardt
  • XOMA

Market driver

  • Increased demand for mAbs
  • For a full, detailed list, view our report

Market challenge

  • Complexities in manufacturing, storage conditions, distribution policies, and high cost
  • For a full, detailed list, view our report

Market trend

  • Emergence of next-generation biologics
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our procurement specialist's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Alternate therapies hinder the growth possibilities of approved therapies

PART 02: Scope of the report

  • Market overview
  • Assumptions
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights
  • Highlights

PART 05: Market landscape

  • Market overview
  • Five forces analysis

PART 06: Market segmentation by product type

  • Global mAbs market
  • Global human insulin market
  • Global clotting factors market
  • Global EPO market
  • Global human growth hormone market

PART 07: Market segmentation by therapy area

  • Metabolic and endocrine disorders
  • Hematopoiesis
  • Fertility
  • Cancer
  • Autoimmune diseases
  • Infectious diseases
  • Protein vaccine

PART 08: Market segmentation by protein function

  • Enzymatic and regulatory activity
  • Special targeting activity
  • Vaccines
  • Protein diagnostics

PART 09: Geographical segmentation

  • Protein therapeutics market in Americas
  • Protein therapeutics market in EMEA
  • Protein therapeutics market in APAC

PART 10: Market drivers

  • Increased demand for mAbs
  • Development of novel therapies using innovative technologies
  • Availability of favorable reimbursement policies

PART 11: Impact of drivers

PART 12: Market challenges

  • Complexities in manufacturing, storage conditions, distribution policies, and high cost
  • Complicated regulatory framework
  • Alternate therapies loom large

PART 13: Impact of drivers and challenges

PART 14: Market trends

  • Emergence of next-generation biologics
  • Advent of biosimilars expected to improve the treatment rates
  • Strategic alliances further boost the R&D efforts

PART 15: Vendor landscape

  • Competitive scenario
  • Market share analysis 2016
  • Other prominent vendors

PART 16: Key vendor analysis

  • F. Hoffmann-La Roche
  • Novo Nordisk
  • Amgen
  • AbbVie
  • Johnson & Johnson
  • Merck

PART 17: Appendix

  • List of abbreviations

PART 18: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Overview of protein therapeutics market 2016-2021
  • Exhibit 03: Key strategies in global protein therapeutics market
  • Exhibit 04: Global protein therapeutics market snapshot: Developed and emerging markets 2015
  • Exhibit 05: Global protein therapeutics market 2016-2021 ($ billions)
  • Exhibit 06: Patent expirations of major biologics 2000-2030
  • Exhibit 07: Impact of factors affecting the market 2016 and 2021
  • Exhibit 08: Five forces analysis
  • Exhibit 09: Segmentation of global protein therapeutics market by product type
  • Exhibit 10: Market share of global protein therapeutics market by product type
  • Exhibit 11: Overview of global mAbs market
  • Exhibit 12: Annual treatment cost per patient for various drugs 2015
  • Exhibit 13: Global mAbs market: Present and future scenario
  • Exhibit 14: Global mAbs market 2016-2021 ($ billions)
  • Exhibit 15: Opportunity analysis of global mAbs market
  • Exhibit 16: Year-over-year (YoY) sales comparison of mAbs 2013-2015 ($ billions)
  • Exhibit 17: Market overview of human insulin
  • Exhibit 18: Global human insulin market 2016-2021 ($ billions)
  • Exhibit 19: Factors affecting global human insulin market
  • Exhibit 20: Opportunity analysis of global human insulin market
  • Exhibit 21: Revenues from the sales of top five products in insulin market 2013-2015 ($ billions)
  • Exhibit 22: Market overview of clotting factors
  • Exhibit 23: Global clotting factors market 2016-2021 ($ billions)
  • Exhibit 24: Opportunity analysis of global clotting factors market
  • Exhibit 25: Market overview of EPO
  • Exhibit 26: Global EPO market 2016-2021 ($ billions)
  • Exhibit 27: Globally approved EPO biosimilars
  • Exhibit 28: Opportunity analysis of global EPO market
  • Exhibit 29: Market overview of human growth hormone
  • Exhibit 30: Global human growth hormone market 2016-2021 ($ billions)
  • Exhibit 31: Opportunity analysis of global human growth hormone market
  • Exhibit 32: Segmentation of global protein therapeutics market by therapy area
  • Exhibit 33: Segmentation of global protein therapeutics market by protein function
  • Exhibit 34: Global protein therapeutics market: Segmentation by geography (2016-2021)
  • Exhibit 35: Global protein therapeutics market segmentation by region: Market growth lifecycle analysis 2016
  • Exhibit 36: Overview of protein therapeutics market in Americas
  • Exhibit 37: Protein therapeutics market in Americas 2016-2021 ($ billions)
  • Exhibit 38: Protein therapeutics market in Americas: Opportunity analysis
  • Exhibit 39: Overview of protein therapeutics market in EMEA
  • Exhibit 40: Protein therapeutics market in EMEA 2016-2021 ($ billions)
  • Exhibit 41: Protein therapeutics market in EMEA: Opportunity analysis
  • Exhibit 42: Overview of protein therapeutics market in APAC
  • Exhibit 43: Protein therapeutics market in APAC 2016-2021 ($ billions)
  • Exhibit 44: Protein therapeutics market in APAC: Opportunity analysis
  • Exhibit 45: mAb approvals by the US FDA and EMA 2010-2015
  • Exhibit 46: Advances in ADCs technology
  • Exhibit 47: Few of other technologies used in protein therapeutics
  • Exhibit 48: Impact of drivers
  • Exhibit 49: Approval process of biologicals versus biosimilars via Public Health Service Act (PHSA) in US
  • Exhibit 50: Few of CAM therapies used for autoimmune and inflammatory diseases
  • Exhibit 51: Impact of drivers and challenges
  • Exhibit 52: Overview of next-generation antibodies
  • Exhibit 53: Oral insulin pipeline portfolio
  • Exhibit 54: Few of the biosimilars under development
  • Exhibit 55: Key deals in global protein therapeutics market
  • Exhibit 56: Market presence of vendors in various therapy areas 2015
  • Exhibit 57: Competitive assessment of vendors
  • Exhibit 58: Geographical presence of key vendors
  • Exhibit 59: F. Hoffmann-La Roche: Profile
  • Exhibit 60: F. Hoffmann-La Roche: Strength assessment
  • Exhibit 61: F. Hoffmann-La Roche: Strategy assessment
  • Exhibit 62: F. Hoffmann-La Roche: Opportunity assessment
  • Exhibit 63: Novo Nordisk: Profile
  • Exhibit 64: Novo Nordisk: Strength assessment
  • Exhibit 65: Novo Nordisk: Strategy assessment
  • Exhibit 66: Novo Nordisk: Opportunity assessment
  • Exhibit 67: Amgen: Profile
  • Exhibit 68: Amgen: Strength assessment
  • Exhibit 69: Amgen strategy assessment
  • Exhibit 70: Amgen: Opportunity assessment
  • Exhibit 71: AbbVie: Profile
  • Exhibit 72: AbbVie: Strength assessment
  • Exhibit 73: AbbVie: Strategy assessment
  • Exhibit 74: AbbVie: Opportunity assessment
  • Exhibit 75: Johnson & Johnson: Profile
  • Exhibit 76: Johnson & Johnson: Strength assessment
  • Exhibit 77: Johnson & Johnson: Strategy assessment
  • Exhibit 78: Johnson & Johnson: Opportunity assessment
  • Exhibit 79: Merck: Profile
  • Exhibit 80: Merck: Strength assessment
  • Exhibit 81: Merck: Strategy assessment
  • Exhibit 82: Merck: Opportunity assessment
Back to Top